JULIO ARRIZABALAGA AGUIRREAZALDEGUI-rekin lankidetzan egindako argitalpenak (20)

2022

  1. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  3. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2018

  1. A case-control study of non-AIDS-defining cancers in a prospective cohort of HIV-infected patients

    Medicina Clinica, Vol. 150, Núm. 8, pp. 291-296

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

2015

  1. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  2. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  2. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230

  2. The Spanish HIV BioBank: A model of cooperative HIV research

    Retrovirology, Vol. 6

2008

  1. Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status

    International Journal of Tuberculosis and Lung Disease, Vol. 12, Núm. 12, pp. 1393-1400

2005

  1. Paludismo por Plasmodium falciparum en viajeros a República Dominicana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 23, Núm. 5, pp. 277-278

2001

  1. Causes of mortality among patients infected with the human immunodeficiency virus in the era of highly active antiretroviral therapy

    Enfermedades infecciosas y microbiología clínica

  2. Granulocyte colony-stimulating factor administration in human immunodeficiency virus-infected patients with prolonged neutropenia

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 19, Núm. 1, pp. 19-23

1999

  1. Abscesos multiples (cerebrales, esplenicos, cutaneos) e infeccion pulmonar

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 17, Núm. 4, pp. 189-190

1998

  1. Utilidad de la desensibilizacion a rifampicina en el tratamiento de enfermedades producidas por micobacterias en pacientes con sida

    Medicina Clinica, Vol. 111, Núm. 3, pp. 103-104